Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

ClinicalTrials.gov ID: NCT01397968

Public ClinicalTrials.gov record NCT01397968. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Study identification

NCT ID
NCT01397968
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
SK Life Science, Inc.
Industry
Enrollment
222 participants

Conditions and interventions

Interventions

  • YKP3089 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 5, 2011
Primary completion
May 31, 2013
Completion
Jan 27, 2021
Last update posted
Apr 10, 2022

2011 – 2021

United States locations

U.S. sites
16
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
St. Joseph Hospital & Medical Center/Barrow Neurology Clinic Phoenix Arizona 85013
Clinical Trials, Inc. Little Rock Arkansas 72205
Kaiser Permanente Anaheim California 92806
VA Greater Los Angeles Healthcare System Los Angeles California 90073
Bradenton Research Center, Inc. Bradenton Florida 34205
Bluegrass Epilepsy Research, LLC Lexington Kentucky 40504
John's Hopkins University School of Medicine Baltimore Maryland 21287
Mid-Atlantic Epilepsy and Sleep Center Bethesda Maryland 20817
Suite 209 South Chesterfield Missouri 63017
Ohio State University Medical Center Columbus Ohio 43210
The University of Toledo Toledo Ohio 43614
Lynn Health Science Institute Oklahoma City Oklahoma 73112
University of Pennsylvania Health System Philadelphia Pennsylvania 19104
Thomas Jefferson University Comprehensive Epilepsy Center Philadelphia Pennsylvania 19107
Neurological Clinic of Texas, P.A. Dallas Texas 75230
University of Virginia Charlottesville Virginia 22903

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01397968, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 10, 2022 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01397968 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →